The “2019 Retinal Pharmaceuticals Market Report” features a new disease model based on disease prevalence by ethnicity, a new discussion on issues with syringes used for IVT injections, new analysis on the competitive features of different drug products, and a new section on orally administered drug candidates in development. The report examines more development-stage programs, biosimilars, gene therapies, anti-inflammatories, and sustained drug-delivery devices. Sales forecasts have been updated through 2024.

What’s New

Market Scope

2019 Retinal Pharmaceuticals Market Report

The 2019 Retinal Pharmaceuticals Market Report analyzes the market for the treatment of retinal diseases and discusses important trends and key factors for future market success. It examines the market’s evolution and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Also covered in this report:

- Discussions of retinal diseases and their risk factors;
- Diagnosis and treatment of these diseases;
- A global view of retinal care and retina specialists;
- Retinal pharmaceuticals and biologics in the marketplace;
- Investigational agents in the development pipeline;
- Profiles of companies developing and marketing retinal pharmaceuticals, plus a listing of additional companies with preclinical programs.

$13B IN MANUFACTURER REVENUES IN 2019

- 89.5% Ophthalmic Labeled Anti-VEGF
- 3.7% Sustained-Release Steroids
- 3.5% Other
- 3.3% IVT Compounded Cancer Drugs
The primary purpose of this report is to analyze the 2019 market in the treatment of retinal diseases and discuss important trends and key factors for future market success. The report looks at the market’s evolution and forecasts growth over the next five years for eight regional markets.

How to Order

Order your “2019 Retinal Pharmaceuticals Market Report” now at www.market-scope.com or contact us directly via email or phone.

Our Process

Market Scope’s industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

- Our proprietary global disease population and demographic models
- Analysis of company-published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in worldwide ophthalmic meetings
- Interviews and relationships with company executives and practicing physicians